Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 7.31
CPIX's Cash-to-Debt is ranked higher than
66% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.05 vs. CPIX: 7.31 )
Ranked among companies with meaningful Cash-to-Debt only.
CPIX' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.16  Med: 12.02 Max: No Debt
Current: 7.31
Equity-to-Asset 0.76
CPIX's Equity-to-Asset is ranked higher than
73% of the 731 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. CPIX: 0.76 )
Ranked among companies with meaningful Equity-to-Asset only.
CPIX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.42  Med: 0.84 Max: 0.91
Current: 0.76
0.42
0.91
Debt-to-Equity 0.10
CPIX's Debt-to-Equity is ranked higher than
83% of the 568 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.30 vs. CPIX: 0.10 )
Ranked among companies with meaningful Debt-to-Equity only.
CPIX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02  Med: 0.09 Max: 0.49
Current: 0.1
0.02
0.49
Piotroski F-Score: 4
Altman Z-Score: 4.29
Beneish M-Score: -2.75
WACC vs ROIC
5.30%
-27.68%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -8.75
CPIX's Operating Margin % is ranked lower than
76% of the 758 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.95 vs. CPIX: -8.75 )
Ranked among companies with meaningful Operating Margin % only.
CPIX' s Operating Margin % Range Over the Past 10 Years
Min: -11.87  Med: 13.72 Max: 23.96
Current: -8.75
-11.87
23.96
Net Margin % -19.57
CPIX's Net Margin % is ranked lower than
77% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.06 vs. CPIX: -19.57 )
Ranked among companies with meaningful Net Margin % only.
CPIX' s Net Margin % Range Over the Past 10 Years
Min: -19.57  Med: 6.84 Max: 14.41
Current: -19.57
-19.57
14.41
ROE % -9.80
CPIX's ROE % is ranked lower than
72% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.91 vs. CPIX: -9.80 )
Ranked among companies with meaningful ROE % only.
CPIX' s ROE % Range Over the Past 10 Years
Min: -9.8  Med: 5.08 Max: 29.02
Current: -9.8
-9.8
29.02
ROA % -7.83
CPIX's ROA % is ranked lower than
72% of the 805 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.71 vs. CPIX: -7.83 )
Ranked among companies with meaningful ROA % only.
CPIX' s ROA % Range Over the Past 10 Years
Min: -7.83  Med: 3.62 Max: 15.88
Current: -7.83
-7.83
15.88
ROC (Joel Greenblatt) % -103.24
CPIX's ROC (Joel Greenblatt) % is ranked lower than
80% of the 793 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.48 vs. CPIX: -103.24 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CPIX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -151.51  Med: 86.86 Max: 1721.07
Current: -103.24
-151.51
1721.07
3-Year Revenue Growth Rate 5.20
CPIX's 3-Year Revenue Growth Rate is ranked higher than
50% of the 634 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. CPIX: 5.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CPIX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -7.4  Med: 5.2 Max: 47.3
Current: 5.2
-7.4
47.3
3-Year EPS without NRI Growth Rate -18.30
CPIX's 3-Year EPS without NRI Growth Rate is ranked lower than
81% of the 576 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.60 vs. CPIX: -18.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CPIX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -48.9  Med: -16.3 Max: 34.2
Current: -18.3
-48.9
34.2
GuruFocus has detected 4 Warning Signs with Cumberland Pharmaceuticals Inc $CPIX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CPIX's 30-Y Financials

Financials (Next Earnings Date: 2017-11-01 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

CPIX Guru Trades in Q3 2016

Jim Simons 247,100 sh (+5.01%)
John Rogers 2,049,760 sh (+2.87%)
» More
Q4 2016

CPIX Guru Trades in Q4 2016

Jim Simons 257,000 sh (+4.01%)
John Rogers 1,824,580 sh (-10.99%)
» More
Q1 2017

CPIX Guru Trades in Q1 2017

Jim Simons 270,240 sh (+5.15%)
John Rogers 1,393,125 sh (-23.65%)
» More
Q2 2017

CPIX Guru Trades in Q2 2017

Jim Simons 290,853 sh (+7.63%)
John Rogers 976,377 sh (-29.91%)
» More
» Details

Insider Trades

Latest Guru Trades with CPIX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Rogers 2017-06-30 Reduce -29.91%0.03%Premium Member Access $6.93 $ 7.062%976,377
John Rogers 2017-06-30 Reduce -29.91%0.03%$5.56 - $7.07 $ 7.067%976,377
John Rogers 2017-03-31 Reduce -23.65%0.03%$5.58 - $7.06 $ 7.0617%1,393,125
John Rogers 2016-12-31 Reduce -10.99%0.01%Premium Member Access $5.5 $ 7.0628%1,824,580
John Rogers 2016-12-31 Reduce -10.99%0.01%$4.7 - $5.72 $ 7.0635%1,824,580
John Rogers 2016-09-30 Add 2.87%$4.45 - $5.01 $ 7.0650%2,049,760
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NAS:AGRX, NAS:MEIP, OTCPK:CBIS, NAS:VERU, OTCPK:CURR, NAS:LPCN, OTCPK:ELTP, OTCPK:COSM, NAS:GALT, NAS:ADMP, NAS:ATXI, NAS:SCYX, OTCPK:OPTI, OTCPK:MCOA, NAS:EVOK, NAS:FCSC, NAS:JNP, NAS:PSDV, OTCPK:SENZ, NAS:BPTH » details
Traded in other countries:CBJ.Germany,
Headquarter Location:USA
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company. It is engaged in the acquisition, development and commercialization of branded prescription products. Its target markets are hospital acute care and gastroenterology.

Cumberland Pharmaceuticals Inc., was incorporated in Tennessee on January 6, 1999. It is a specialty pharmaceutical company which is engaged in the acquisition, development and commercialization of branded prescription products. It operates in a single operating segment of specialty pharmaceuticals products. Its product portfolio includes Acetadote (acetylcysteine) Injection for the treatment of acetaminophen poisoning, Caldolor (ibuprofen) Injection, the first injectable treatment for pain and fever approved in the United States, Kristalose (lactulose) for Oral Solution, a prescription laxative, and Hepatoren (ifetroban) injection, a Phase II candidate for the treatment of critically ill hospitalized patients suffering from hepatorenal syndrome (HRS). The Company's target markets are hospital acute care and gastroenterology, which are characterized by concentrated physician bases that it believe can be penetrated effectively by relatively small, targeted sales forces. The Company markets and sells its products through its dedicated hospital and gastroenterology sales forces in the United States, which together comprised more than 65 sales representatives and managers as of March 1, 2013. Acetadote is an intravenous formulation of N-acetylcysteine, or NAC, indicated for the treatment of acetaminophen poisoning. Caldolor, its intravenous formulation of ibuprofen, was the first injectable product approved in the United States for the treatment of both pain and fever. Kristalose is a prescription laxative administered orally for the treatment of constipation. Hepatoren is in Phase II clinical development. Pharmaceutical companies are subject to extensive regulation by national, state, and local agencies in the U.S. and additional regulations in other countries in which do business. It promotes Acetadote and Caldolor through its dedicated hospital sales team and currently utilize two distinct sales teams to address its primary target markets: a hospital sales force for the acute care market and a field sales force for the gastroenterology market. It competes with the product attributes such as efficacy, safety, ease-of-use and cost-effectiveness.

Ratios

vs
industry
vs
history
PB Ratio 1.68
CPIX's PB Ratio is ranked higher than
75% of the 751 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.80 vs. CPIX: 1.68 )
Ranked among companies with meaningful PB Ratio only.
CPIX' s PB Ratio Range Over the Past 10 Years
Min: 0.9  Med: 1.31 Max: 4.83
Current: 1.68
0.9
4.83
PS Ratio 3.17
CPIX's PS Ratio is ranked lower than
53% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.97 vs. CPIX: 3.17 )
Ranked among companies with meaningful PS Ratio only.
CPIX' s PS Ratio Range Over the Past 10 Years
Min: 1.65  Med: 2.69 Max: 6.81
Current: 3.17
1.65
6.81
EV-to-EBIT -23.70
CPIX's EV-to-EBIT is ranked lower than
99.99% of the 559 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.11 vs. CPIX: -23.70 )
Ranked among companies with meaningful EV-to-EBIT only.
CPIX' s EV-to-EBIT Range Over the Past 10 Years
Min: -377.8  Med: 8.25 Max: 993.7
Current: -23.7
-377.8
993.7
EV-to-EBITDA -170.67
CPIX's EV-to-EBITDA is ranked lower than
89% of the 587 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.50 vs. CPIX: -170.67 )
Ranked among companies with meaningful EV-to-EBITDA only.
CPIX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -174.58  Med: 8.4 Max: 62.6
Current: -170.67
-174.58
62.6
EV-to-Revenue 1.95
CPIX's EV-to-Revenue is ranked higher than
70% of the 755 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.22 vs. CPIX: 1.95 )
Ranked among companies with meaningful EV-to-Revenue only.
CPIX' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.2  Med: 1.2 Max: 6.2
Current: 1.95
0.2
6.2
Shiller PE Ratio 67.09
CPIX's Shiller PE Ratio is ranked lower than
58% of the 198 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 39.37 vs. CPIX: 67.09 )
Ranked among companies with meaningful Shiller PE Ratio only.
CPIX' s Shiller PE Ratio Range Over the Past 10 Years
Min: 21.7  Med: 29.32 Max: 68.05
Current: 67.09
21.7
68.05
Current Ratio 4.88
CPIX's Current Ratio is ranked higher than
75% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. CPIX: 4.88 )
Ranked among companies with meaningful Current Ratio only.
CPIX' s Current Ratio Range Over the Past 10 Years
Min: 1.45  Med: 5.72 Max: 14.46
Current: 4.88
1.45
14.46
Quick Ratio 4.45
CPIX's Quick Ratio is ranked higher than
76% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.82 vs. CPIX: 4.45 )
Ranked among companies with meaningful Quick Ratio only.
CPIX' s Quick Ratio Range Over the Past 10 Years
Min: 1.38  Med: 5.3 Max: 13.46
Current: 4.45
1.38
13.46
Days Inventory 291.54
CPIX's Days Inventory is ranked lower than
93% of the 707 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 117.36 vs. CPIX: 291.54 )
Ranked among companies with meaningful Days Inventory only.
CPIX' s Days Inventory Range Over the Past 10 Years
Min: 110.73  Med: 381.63 Max: 636.33
Current: 291.54
110.73
636.33
Days Sales Outstanding 61.62
CPIX's Days Sales Outstanding is ranked higher than
72% of the 651 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.70 vs. CPIX: 61.62 )
Ranked among companies with meaningful Days Sales Outstanding only.
CPIX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 30.88  Med: 51.09 Max: 81.01
Current: 61.62
30.88
81.01
Days Payable 353.00
CPIX's Days Payable is ranked higher than
97% of the 600 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.96 vs. CPIX: 353.00 )
Ranked among companies with meaningful Days Payable only.
CPIX' s Days Payable Range Over the Past 10 Years
Min: 103.04  Med: 225.25 Max: 496.99
Current: 353
103.04
496.99

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 3.70
CPIX's 3-Year Average Share Buyback Ratio is ranked higher than
98% of the 473 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.10 vs. CPIX: 3.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CPIX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -7  Med: 2.1 Max: 5.1
Current: 3.7
-7
5.1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 4.03
CPIX's Price-to-Net-Cash is ranked higher than
87% of the 239 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.21 vs. CPIX: 4.03 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CPIX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.37  Med: 2.26 Max: 6.72
Current: 4.03
1.37
6.72
Price-to-Net-Current-Asset-Value 2.67
CPIX's Price-to-Net-Current-Asset-Value is ranked higher than
86% of the 512 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.25 vs. CPIX: 2.67 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CPIX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.07  Med: 1.7 Max: 5.38
Current: 2.67
1.07
5.38
Price-to-Tangible-Book 2.51
CPIX's Price-to-Tangible-Book is ranked higher than
67% of the 690 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.51 vs. CPIX: 2.51 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CPIX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.04  Med: 1.62 Max: 5.21
Current: 2.51
1.04
5.21
Price-to-Intrinsic-Value-Projected-FCF 1.88
CPIX's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
68% of the 328 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. CPIX: 1.88 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
CPIX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.7  Med: 1.1 Max: 1.9
Current: 1.88
0.7
1.9
Price-to-Median-PS-Value 1.17
CPIX's Price-to-Median-PS-Value is ranked lower than
59% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.09 vs. CPIX: 1.17 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CPIX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.63  Med: 1.01 Max: 2.41
Current: 1.17
0.63
2.41
Earnings Yield (Greenblatt) % -4.21
CPIX's Earnings Yield (Greenblatt) % is ranked lower than
75% of the 805 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. CPIX: -4.21 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CPIX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -18.2  Med: 5.1 Max: 79.2
Current: -4.21
-18.2
79.2
Forward Rate of Return (Yacktman) % -0.63
CPIX's Forward Rate of Return (Yacktman) % is ranked lower than
70% of the 380 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.46 vs. CPIX: -0.63 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
CPIX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -0.63  Med: 3.9 Max: 18.9
Current: -0.63
-0.63
18.9

More Statistics

Revenue (TTM) (Mil) $36.18
EPS (TTM) $ -0.44
Beta0.53
Short Percentage of Float1.13%
52-Week Range $4.60 - 7.49
Shares Outstanding (Mil)15.90
» More Articles for CPIX

Headlines

Articles On GuruFocus.com
Cumberland Pharmaceuticals To Announce Second Quarter 2017 Financial Results Aug 01 2017 
Cumberland Pharmaceuticals Begin U.S. Shipments Of Dexrazoxane For Oncology Patient Support Jul 31 2017 
Cumberland Pharmaceuticals to Announce First Quarter 2017 Financial Results May 08 2017 
New Kristalose® Growth Driver Established Through Co-Promotion Agreement Apr 26 2017 
Micro Cap Value Discovery Jul 05 2016 
Speculative Options Buys Apr 29 2011 
Cumberland Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 11 2011 
Cumberland Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 15 2010 
Cumberland Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 16 2010 
Cumberland Pharmaceuticals Inc. Reports Operating Results (10-Q) May 17 2010 

More From Other Websites
What Are The Drivers Of Cumberland Pharmaceuticals Inc’s (CPIX) Risks? Sep 13 2017
Edited Transcript of CPIX earnings conference call or presentation 8-Aug-17 8:30pm GMT Aug 17 2017
Cumberland reports 2Q loss Aug 08 2017
Cumberland Pharmaceutical Reports Double Digit Revenue Growth For The Fourth Consecutive Quarter Aug 08 2017
Investor Network: Cumberland Pharmaceuticals Inc. to Host Earnings Call Aug 08 2017
Cumberland Pharmaceuticals To Announce Second Quarter 2017 Financial Results Aug 01 2017
Cumberland Pharmaceuticals Begin U.S. Shipments Of Dexrazoxane For Oncology Patient Support Jul 31 2017
ETFs with exposure to Cumberland Pharmaceuticals, Inc. : July 12, 2017 Jul 12 2017
ETFs with exposure to Cumberland Pharmaceuticals, Inc. : May 25, 2017 May 25 2017
Cumberland Pharmaceuticals, Inc. :CPIX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017 May 24 2017
Edited Transcript of CPIX earnings conference call or presentation 15-May-17 8:30pm GMT May 21 2017
Cumberland Pharmaceuticals Reports Revenue Growth Of 25% In First Quarter 2017 May 15 2017
Cumberland Pharmaceuticals to Announce First Quarter 2017 Financial Results May 08 2017
New Kristalose® Growth Driver Established Through Co-Promotion Agreement Apr 26 2017
Caldolor® Demonstrates Significant Post Surgical Pain Reduction and Decrease in Opioid Use Mar 27 2017
INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of... Mar 22 2017
Cumberland Pharmaceuticals, Inc. :CPIX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21,... Mar 21 2017
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of... Mar 17 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}